Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysis

02 Jun 2020 (Last Updated June 2nd, 2020 10:18)

The Covid-19 pandemic has left pharmaceutical companies, particularly those in the psychiatry space, contending to learn the disaster’s impact on patient-reported outcomes (PROs) utilised in studies and similar subjective measures that calculate patient or caregiver emotions.

To salvage PROs, as well as other results for studies in any therapeutic area that started before the beginning of the pandemic, clients are advised to translate data collected pre-, during and post-Covid-19, as well as conduct sensitivity analysis. Read more here.